Last Updated: July 28, 2026

Litigation Details for Best Medical International, Inc. v. Varian Medical Systems, Inc. (D. Del. 2018)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Best Medical International, Inc. v. Varian Medical Systems, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation summary and analysis for: Best Medical International, Inc. v. Varian Medical Systems, Inc. (D. Del. 2018)

Last updated: July 17, 2026

Best Medical International, Inc. v. Varian Medical Systems, Inc. | 1:18-cv-01599 litigation summary and IP analysis

Executive summary: The docket 1:18-cv-01599 is associated with Best Medical International, Inc. asserting patent rights against Varian Medical Systems, Inc. The case is litigation-focused, with typical infringement and validity issues tied to medical device or related imaging/radiotherapy technology. A litigation summary and strength analysis is not provided here because the record content required to produce a complete, accurate, business-grade view (claims-in-suit, asserted patents, court rulings, Markman outcomes, settlement status, and any dispositive decisions) is not present in the provided input.

What patents were asserted in Best Medical International v. Varian Medical Systems (1:18-cv-01599)?

Featured snippet: The asserted patent numbers and claim sets for 1:18-cv-01599 are not provided in the input.

Which patent holders and assignees appear in the case caption?

  • Not provided in the input.

Which jurisdictions and forums were involved beyond the district court?

  • Not provided in the input.

What did the court rule in 1:18-cv-01599: motions to dismiss, transfer, or claim construction?

Featured snippet: The key rulings (including claim construction and dispositive orders) are not provided in the input.

Were there Markman hearings and what constructions mattered?

  • Not provided in the input.

Were there summary judgment decisions on infringement or invalidity?

  • Not provided in the input.

Did the case end by dismissal, final judgment, or settlement?

  • Not provided in the input.

Did Best Medical file a Paragraph IV-type challenge or was the dispute purely infringement?

Featured snippet: The input does not establish whether the matter involves an FDA exclusivity/Orange Book framework or is strictly a patent infringement suit.

Was this an FDA regulatory litigation posture (ANDA/BLA) or a device patent dispute?

  • Not provided in the input.

What remedies were sought (injunction, damages, declaratory relief)?

  • Not provided in the input.

How strong is the patent estate for Best Medical in this dispute?

Featured snippet: Strength cannot be evaluated without the asserted patents, their expiration dates, prosecution history, and litigation claim constructions.

What is the timeline from filing to key infringement/validity outcomes?

  • Not provided in the input.

Any estoppel or admissibility effects from prior PTAB or earlier district litigation?

  • Not provided in the input.

What generic entry risks exist if this is an infringement case tied to a regulated product?

Featured snippet: Not applicable based on the missing linkage between the docket and any specific marketed product launch, exclusivity, or regulatory pathway.

Is there an Orange Book or device-equivalent exclusivity link?

  • Not provided in the input.

Do concurrent litigations by other competitors suggest coordinated risk?

  • Not provided in the input.

What Varian defenses were raised in 1:18-cv-01599 (non-infringement, invalidity, inequitable conduct)?

Featured snippet: The input does not include the defense themes or claim-by-claim positions.

Non-infringement: how did Varian contest claim elements?

  • Not provided in the input.

Invalidity: anticipation/obviousness posture and key references

  • Not provided in the input.

Conduct defenses: inequitable conduct or prosecution disclaimer

  • Not provided in the input.

How does this case compare with other Varian patent litigations (similar technology, similar venues)?

Featured snippet: Comparative analysis requires docket-level outcomes and asserted-technology mapping, which are not in the input.

Were there similar disputes with other medical device competitors?

  • Not provided in the input.

Did any prior Federal Circuit or district court rulings shape this matter?

  • Not provided in the input.

Key litigation timeline (filings, rulings, settlements)

Featured snippet: The timeline cannot be constructed without docket events.

Date Docket event Practical impact on the patent dispute
Not provided Not provided Not provided

What is the current status of Best Medical v. Varian (1:18-cv-01599)?

Featured snippet: The input does not include current case status, judgment entry, or settlement indicators.

Key Takeaways

  • A litigation summary and IP strength analysis for Best Medical International, Inc. v. Varian Medical Systems, Inc. (1:18-cv-01599) cannot be produced from the provided input because the record details required for accuracy are missing.
  • Business conclusions that depend on asserted patents, claim constructions, and dispositive rulings are not supported by the provided information.

FAQs

  1. What court handled 1:18-cv-01599 and which judge was assigned?
  2. Which patents (numbers and filing dates) were asserted by Best Medical in 1:18-cv-01599?
  3. What claim construction outcomes influenced infringement or invalidity in 1:18-cv-01599?
  4. Did 1:18-cv-01599 resolve via settlement, and what were the license terms if any?
  5. Are there related PTAB inter partes review proceedings tied to the asserted patents?

References

  1. Not provided in the input.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.